Despite being a first-line treatment for CHE, nearly 40% of patients treated with TCS had inadequate treatment response or contraindications to TCS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback